Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.
Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

National Drug Formulary

AQUIPTA TABLET 60MG [SIN17146P]

Active ingredients: ATOGEPANT MONOHYDRATE EQV ATOGEPANT

View product's general information
Last updated on 9 October 2026

Product Info

AQUIPTA TABLET 60MG

[SIN17146P]

Product information

Active Ingredient and Strength

ATOGEPANT MONOHYDRATE EQV ATOGEPANT - 60 MG

Dosage Form

TABLET

Manufacturer and Country

FOREST LABORATORIES IRELAND, LIMITED - IRELAND

Registration Number

SIN17146P

Licence Holder

ABBVIE PTE. LTD.

Forensic Classification

PRESCRIPTION ONLY MEDICINES

Anatomical Therapeutic Chemical (ATC) code

N02CD07

Prescription-only Medicines with Exemptions for Supply without Prescription

NA

Indication

2. INDICATIONS

AQUIPTA™ is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Dosing

3. DOSAGE AND ADMINISTRATION

3.1 Recommended dosage

The recommended dosage for AQUIPTA™ is 60 mg taken orally once daily with or without food.

There is no data that the 60 mg tablet can be divided into equal halves.

3.2 Missed dose

A missed dose should be taken right away. If it is almost time for the next dose, patients should be instructed to skip the missed dose and take the next dose as scheduled.

3.3 Dose modification

Dosing modifications for concomitant use of specific drugs (see DRUG INTERACTIONS – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information) and for patients with renal impairment are provided in Table 1.

Aquipta Dosage Table 1



3.4 Dosing in special populations

3.4.1 Pediatrics

Safety and effectiveness of AQUIPTA™ in pediatric patients have not been established.

3.4.2 Geriatric

Population pharmacokinetic modeling suggests no clinically significant pharmacokinetic differences between elderly and younger subjects. No dose adjustment of AQUIPTA™ is needed in elderly patients.

3.4.3 Renal impairment

For patients with severe renal impairment and ESRD, see dose adjustment in Table 1. No dose adjustment is recommended for patients with mild or moderate renal impairment.

For patients with ESRD undergoing intermittent dialysis, AQUIPTA™ should preferably be taken after dialysis.

3.4.4 Hepatic impairment

Avoid use of AQUIPTA™ in patients with severe hepatic impairment (Child-Pugh Class C) (see PHARMACOLOGIC PROPERTIES – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information). No dose adjustment is recommended for patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.

Contraindications

4. CONTRAINDICATIONS

AQUIPTA™ is contraindicated in patients with a history of hypersensitivity to atogepant or any of the components of AQUIPTA™. Reactions have included anaphylaxis and dyspnea (see WARNINGS AND PRECAUTIONS – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information).